Latest lecanemab data to be presented at the AD/PD™ congress
Stockholm, March 11, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401), at the 16th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2022 in Barcelona and online.The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders is a key scientific event with a focus on improving the treatment of Alzheimer’s,